Similar articles

• Pharmacology of carvedilol.

  Dulin B, Abraham WT. Dulin B, et al. Am J Cardiol. 2004 May 6;93(9A):3B-6B. doi: 10.1016/j.amjcard.2004.01.003. Am J Cardiol. 2004. PMID: 15144929 Review.
• Clinical pharmacology of multiple action compounds.

  Prichard BN, Tomlinson B. Prichard BN, et al. Z Kardiol. 1989;78 Suppl 3:1-6. Z Kardiol. 1989. PMID: 2573211 Review.
• Bucindolol: effects on blood pressure, airways resistance and serum creatine phosphokinase.

  Gill JS, Beevers DG. Gill JS, et al. Eur J Clin Pharmacol. 1984;27(3):265-8. doi: 10.1007/BF00542157. Eur J Clin Pharmacol. 1984. PMID: 6150855
• Pharmacology of bucindolol in isolated canine vascular smooth muscle.

  Rimele TJ, Aarhus LL, Lorenz RR, Rooke TW, Vanhoutte PM. Rimele TJ, et al. J Pharmacol Exp Ther. 1984 Nov;231(2):317-25. J Pharmacol Exp Ther. 1984. PMID: 6149305
• Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor.

  Maack C, Böhm M, Vlaskin L, Dabew E, Lorenz K, Schäfers HJ, Lohse MJ, Engelhardt S. Maack C, et al. Circulation. 2003 Jul 22;108(3):348-53. doi: 10.1161/01.CIR.0000080325.94345.8B. Epub 2003 Jul 7. Circulation. 2003. PMID: 12847069